Investor Relations

Investor Relations Home

Stock Information
Corporate Profile

Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to addressing unmet needs of patients by bringing innovative solutions to the field of dermatology. The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo. Having completed Phase II clinical trials of these product candidates, the company expects ... More >>

Recent NewsMore >>
06/15/17Foamix Pharmaceuticals to Present at the 2017 BIO International ConventionPrinter Friendly Version
06/12/17Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%Printer Friendly Version
06/01/17Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare ConferencePrinter Friendly Version
05/09/17Foamix Reports First Quarter 2017 Financial Results and Provides Business UpdatePrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Foamix Pharmaceuticals Ltd posts new information to the site. Just enter your e-mail address and click Submit.